Home
Clinical Resources Search
PQI: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

Download PQI pdf 0.23MB

Last Updated: May 3, 2024

By: Paige Reid, PharmD

About this PQI

Tepotinib is an oral tyrosine kinase inhibitor (TKI) designed specifically to target mesenchymal epithelial transition exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC).1 This PQI will discuss safety, efficacy, strategies for dosing, and side effect management.

More About This PQI

PQI in Action Articles:

tepotinib_tepmetko_NSLC pdf 1.3MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Non-Small Cell Lung Cancer (NSCLC) Tepmetko Tepotinib

PQI

Frequently Searched

Supported by

Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

PQI in Action: Proactive Symptom Management in Myelofibrosis

PQI in Action: Sonidegib (Odomzo®) Patient Management

S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice

S8 Bonus Eps 2: Inside ASCO 2025

S8 E15: Supporting Survivors at Work

S8 E14: Advancing Geriatric Oncology

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC

S8 Ep 12: Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice

Treatment Support Kit: Elranatamab